trending Market Intelligence /marketintelligence/en/news-insights/trending/jmwRbrANaBpA87zNLBnm4w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Paratek pulls EU application for Nuzyra after request for 2nd pneumonia study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Paratek pulls EU application for Nuzyra after request for 2nd pneumonia study

Paratek Pharmaceuticals Inc. withdrew an application with the European Medicines Agency for marketing approval of Nuzyra for treating certain infections and a common type of pneumonia.

Paratek withdrew the application after the regulator said it would recommend approving the therapy for acute bacterial skin and skin structure infections but not for community-acquired bacterial pneumonia. The EMA said Paratek would have to complete another study to earn a nod for the pneumonia indication.

The Boston-based biopharmaceutical company said in an Oct. 17 press release that the directive is consistent with the EU body's requirement for two phase 3 studies to secure approval in community-acquired bacterial pneumonia.

The application for Nuzyra, or omadacycline, was supported by a phase 3 program that included three studies, two in the infection indications and one for pneumonia. Those trials met their goals, and the therapy was determined to be safe and well tolerated by patients.

Paratek said securing approval in both indications for Nuzyra remains its top priority to maximize value. The approval would bring with it 10 years of market exclusivity.

Nuzyra, a once-daily oral and intravenous medication, is already approved by the U.S. Food and Drug Administration in acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.